📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Affle 3i Limited Grants 1.37 Lakh Stock Options Under ESOP Scheme 2021
Affle 3i Limited has announced the grant of 1,37,080 stock options to eligible employees under its Employee Stock Option Scheme 2021. The options are convertible into equity shares of face value Rs. 2 each, with the exercise price set at the closing market price on January 27, 2026. The vesting schedule is staggered over a four-year period to ensure long-term employee retention. This is a standard corporate procedure for technology-driven companies to align employee interests with shareholder value.
Key Highlights
Total of 1,37,080 stock options granted to eligible employees on January 28, 2026
Exercise price is based on the NSE closing price of January 27, 2026
77,480 options vest at 25% annually over a period of 48 months
59,600 options follow a back-ended vesting with 50% at 24 months and 25% in years 3 and 4
The exercise period for the options is one year from the date of vesting
💼 Action for Investors
This is a routine administrative update for talent retention and requires no immediate action from investors. Long-term investors should track the cumulative equity dilution resulting from such ESOP grants in the company's annual filings.
Affle 3i Limited Schedules Q3 & 9M FY2026 Earnings Call for February 2, 2026
Affle 3i Limited (formerly Affle India Limited) has announced its earnings conference call for the third quarter and nine months ended December 31, 2025. The call is scheduled for Monday, February 02, 2026, at 10:00 AM IST. Senior management, including the MD & CEO and the CFO, will be present to discuss financial results and business developments. This is a routine but essential event for stakeholders to understand the company's growth trajectory in the digital advertising space.
Key Highlights
Earnings call scheduled for February 02, 2026, at 10:00 AM IST
Covers financial performance for Q3 and 9M ended December 31, 2025
Management representation includes Chairperson, MD & CEO Anuj Khanna Sohum and CFO Kapil Bhutani
Universal dial-in numbers provided: +91 22 6280 1386 and +91 22 7115 8287
International toll-free access available for USA, UK, Singapore, Hong Kong, and Japan
💼 Action for Investors
Investors should attend the call or review the transcript to assess management's outlook on ad-tech spending and the impact of the company's recent rebranding. Focus on key metrics like CPCU (Cost Per Converted User) growth and international expansion updates.